Defining disease stability in COPD: Evidence from Phase 3 clinical trials

The authors aimed to characterize disease stability in chronic obstructive pulmonary disease (COPD) as a composite endpoint and assess its prognostic value for long-term outcomes. Their analyses from multiple Phase 3 clinical trials indicated that achieving stability—defined as no moderate/severe exacerbations and no worsening in symptoms—was associated with significant reductions in the risk of exacerbations and all-cause mortality. The findings support the notion of disease stability as a viable treatment target in COPD, with implications for improving patient outcomes.